







WHY ADDRESSING OBESITY AND LIFESTYLE IN CANCER SURVIVORS MATTERS

Melinda Stolley, PhD Professor, Department of Medicine Associate Director of Cancer Prevention and Control




PROJECTED INVASIVE CANCER INCIDENCE 2010-2030

- 142% increase among Hispanics
- 60% increase among African Americans



Smith BD Clin Oncol. 2009;27(17):2758-2765.



Utah, Adanta, San Jose-Monteney, Los Angeles, Alaska Native Registry, Raral Georgia, California exchaling SUSIV/LA. Centucky, Louisiana, New Jersey, and Georgia excluding ATL/RG.

The relative survival rates are calculated using monthly intervals.

The Expected Servival Ufs Tables [https://seer.carcer.gov/expserviva/] by Socio-Economic Standards were used.

Rates for American Indians/Alaska Natives only include cases that are in a Parchased/Referred Care Delivery Area (PRCOA). See: SEER Rare Records Documentation for American Indian/Alaskan Native Statistics (http://see.cancer.gov/seersnat/variables/seer/rare, ethnicity(#si-an].

Hispanics and Non-Hispanics are not mutually exclusive from whites, blacks, Asian/Racific Islanders, and American Indians/Alaska. Natives, incidence data for Hispanics and Non-Hispanics are based on the NAACCR Hispanic Latino Identification Algorithm (NHA). and exclude cases from the Alaska Native Registry. See SER Bace Leonde Documentation for Spanish-Hispanic-Latino Printicity. [http://saar.cancer.gov/seerstat/variablas/seer/raca_ethinkthy/#htpank].

See 4a http://https://see.cancer.gov/explorer/cancer_sites/httm?>SEEP*Explorer_Cancer_Site Definitions «fa» for details about the coding used for SEER Incidence data.

Created by weer sameer, gov/explorer/application.php. on 04/19/2019 3:55 pm.

The Expected Servival Ufp Tables [https://seer.canoor.gov/expservival/] by Socio-Economic Standards were used. Rates for American Indians/Alaska Natives only include cases that are in a Parchased/Referred Care Delivery Area (PRCD4). See: SEER Rare Records Documentation for American Indian/Alaskan Native Statistics (http://seer.cancer.gou/seersanivariablet/seer/rare, ethnicity(Pai-an]. Hispanics and Non-Hispanics are not mutually exclusive from whites, blacks, Asian/Racific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on the NAACCR Hispanic Latino Identification Algorithm (NHA). and exclude cases from the Alaska Native Registry. See SER Race Leonde Documentation for Spanish-Hispanic-Latino Printicity. [http://ser.cancer.gov/seerstat/variables/seer/race_ethinktly/Whispank].


See =a href="https://seen.cancer.govfexplorer/cancer_sites/html">SEER*Explorer_Cancer_Site_Definitions «fa> for details about the coding used for SEER Incidence data.

Created by seer samer, gov (explorer/ application, php. on 04/19/2019 3:47 pm.

Louisiana, New Jersey, and Georgia excluding ATL/RG.

The relative survival rates are calculated using monthly intervals.

TRENDS IN OBESITY PREVALENCE IN ADULTS WITH CANCER (1997-2014)



Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies

Study	Per 5 kg/m ² BM BB (95% Cl)	% Weight	Słudy	RF (06% CI)	Weight	Rull Rg/m²
Pre-ciagnosis BMI			Underweight v normal weight Alsaker 2011	0.98 (0.38, 1.19)	8.17	<20 v 20-24.9
Kamireni 2013	1.14 (0.88, 1.47)	1.62	Carroy 2011	1.22 (0.57, 1.71)	16.83	<22.5 v 22.5-24.5
		1.95	Lu 2011	0.55 (0.55, 1.12)	21.45	<20 v 20-24.9
Conroy 2011	1.28 (1.14, 1.46)		Emaus 2010 Hailmana 2010	1.49 (0.56, 3.37) 1.77 (0.90, 3.19)	4.25	<18.5 x 18.5-25 x=19.9 x 20-25
	1.09 (1.00, 1.19)	13.36	Nichola 2009	0.20 (0.22, 5.85)	1.46	<=18.4 v 18.5-241
Chen 2010	1.15 (1.01, 1.32)	5.79	Kiconka 2006	0.88 (0.85, 1.12)	19.17	<21 V 21-52 <=18.5 V 18.51-25
maus 2010	1.14 (1.00, 1.30)	6.15	Whiteman 2006 Subrotal (/ squared = \$1.1%, P = 0.170)	1.07 (0.81, 1.41) 1.02 (0.95, 1.21)	21.05	<=18.5 V 18.51-2
telinarin 2010 -	1.26 (1.05, 1.52)	3.21		Trade Perioda, Tracty	00.00	
lichols 2009	1,20 (1.06, 1.35)	7.26	Overweight v normal weight Kamineni 2013			
Vast-Wright 2009	1.15(1.01, 1.31)	5.89	Abahar 2011	1.45 (0.52, 5,38) 1.14 (0.96, 1.35)	0.35	25-23.9 v <25 25-23.9 v 20-24
laan 2008	1.26 (1.05, 1.52)	3.12	Correy 2011	1.17 (0.56, 1.55)	3.05	25-29.9 v 22.5-2
lai Maso 2008	1.11 (0.98, 1.26)	6.61	Lu 2011 1	0.99 (0.53, 1.15)		25-29.9 u 20-24
			Emaus 2010 Holimone 2010	1.01 (0.79, 1.30) 1.29 (0.84, 1.70)	4.64	25 1-29 9 V 18 5 25 1-30 V 20-25
eding 2008	1.17 (1.10, 1.23)	26.25	Nichola 2009	1.48 (0.28, 5.24)	1,66	25-29.9 0 18:5-3
bishamson 2006	1.62 (1.16, 1.99)	1.49	Rosonberg 2009	0.30 (0.70, 1.20)	3.86	25-30 v -=24.8
9roenke 2006	- 1.13 (1.02, 1.25)	9.06	West Wright 2009 Caan 2003	1.16 (0.83, 1.52) 1.40 (0.90, 2.30) 1.07 (0.95, 1.35)	2.62	25-23 v ↔24 25-23.9 v <=24.0
hang 1996	1.14 (0.93, 1.39)	2.60	Da Maso 2008	1.07 (0.55, 1.35)	5.27	25-23.9 v <= 34.9
felmberg 1994	1.47 (1.14, 1.89)	1.67	Resves 2007	1.05 (0.00, 1.20) 1.12 (0.98, 1.43)	0.74	25
Libtotal (f-squared = 6.6%, P = 0.379)	1.17 (1.18, 1.21)	100.00	Kroenke 2005 Writeman 2005	1.12 (0.98, 1.43) 1.25 (1.98, 1.44)	4.76	25-23 y 21-22 25-23 9 y cm22.1
			Enger 2004	0.59 (0.52, 1.25)		22-24.8 y <23.4
MI <12 months after diagnosis			Meetile 2004	1.03 (0.87, 1.40)		Q2-C6 v Q1
wartz 2012	1.08 (0.99, 1.19)	10.73	Scharpt 1999 Galonic 1993	1.30 (0.90, 1.70) 1.70 (0.90, 4.50)		23.34-26.15 P m 22.7-25.7 V <= 2
			_501 1994	1.20 (0.75, 1.91)	1.59	24.14-27.34 #-0
ioodwin 2012	1.12 (0.94, 1.34)	4.97	Tomberg 1993	1.40 (1.00, 1.90)	2.74	26-27 V <=21
Sewei 2012	1.52 (0.89, 2.60)	0.71	Troti 1650 Subrotal (/ squared = 0.0%, P = 0.856)	1.06 (0.96, 1.24) 1.11 (1.06, 1.17)	16.38	Q1 v Q1
aumgarther 2011	0.94 (0.83, 1.06)	7.91	Georgen (, administra = crawy, h = orage)	1.11(1.26, 1.17)	00.00	
zambuja 2010 -	- 1.17 (1.06, 1.29)	10.00	Opese v normal weight			
Chen 2010	1.13 (0.99, 1.29)	7.01	Kamineni 2013 Abahar 2011	2.41 (1.00. 5.31) 1.52 (1.25, 1.85)	0.66	>=30 y =25 >=30 y 20-24
Dawood 2000	1.12 (0.96, 1.30)	6.00	Carroy 2011	1.65 (1.05, 2.00)		>=30 y 22.5-24.5
Aaied 2000	1.05 (1.01, 1.10)	16.49	Lu 2011	1.20 (0.99, 1.45)	8.34	3=30 y 20-24 B
Atolias 2009	1.22 (1.10, 1.34)	10.03	Emaus 2010	1.43 (1.01, 2.02)	4.28	5=30 V 18.5-25
biahamson 2003	1.27 (1.11, 1.45)	7.20	Heimans 2010 Richols 2009	1.82 (1.11, 2.90) 1.42 (0.88, 5.98)	2.56	>30 V 20-25 >+30 V 18.5-24.9
ac 2006		2.78	Rosonbarg 2009 West Wright 2000	1.20 (0.30, 1.60) 1.71 (1.16, 2.53)	5.49	> 30 v <36
	1.30 (1.01, 1.68)		West Wright 2000	1.71 (1.16, 2.53)	3.60 2.06	>=30 y =26 >=30 y ==24.0
Berdaz 2004	1.07 (1.02, 1.12)	15.58	Caan 2003 Dai Mase 2000	1.50 (0.00, 2.70) 1.00 (1.02, 1.30)	5.10	>=30 y <=24.9
obiotal (Asquared = 54.8%, P = 0.011)	1.11 (1.06, 1.16)	100.00	Cleveland 2007	1.00 (1.02, 1.00) 1.00 (1.04, 5.34) 1.12 (0.73, 1.73)	1.60	>90 x <24.9
			Reaves 2007	1.12 (0.73. 1.73)	3.05	2=30 y 16.5-25
MI >=12 months after diagnosis	-		Kisenke 2005 Wittemen 2005	1.09 (0.90, 1.48) 1.24 (1.09, 1.55)		>=30 7 21-22 >=30 7 c=22.8
Batt 2010 -	1.11 (0.98, 1.27)	28.42	Enger 2004	0.76 (0.53, 1.07)	4.20	5=21.9 u c23.4
lichols 2009	1.10 (0.98, 1.24)	36.22	Machie 2004	1.38 (1.04, 1.84)	5.55	Q5 V Q1
aan 2009	1.14 (0.92, 1.42)	10.34	Gatanic 1993	1.80 (1.20, 2.10) 2.20 (0.30, 6.40)		5-28.15% <-21.3 >-25.8% <-21.6
wartz 1991	0.99 (0.86, 1.13)	26.01	Join 1994	0.78 (0.48, 1.22)		>27 34 v <22.22 >-28 v +=21
			Temberg 1003	1.70 (1.20, 2.30)	4.E7	>=28 + +=21
Subtotal (Fequaled = 0.0%, P = 0.517)	1.08 (1.01, 1.16)	100.00	Trati 1950 Subrotel (P-squered = 55.5% P = 0.051)	1.35 (1.10, 1.54) 1.35 (1.24, 1.47)	10.07	Q5 v Q1
				1.34 (1.24, 1.47)	00.00	
	1			1		
0.5 1	2		0.125 1	B		

All cause mortality

BC specific mortality

Chan DS, Ann Orcol. 2014;25(10):1901-1914.


OBESITY AND PROSTATE CANCER MORTALITY

Shared Equal Access Regional Cancer Hospital (SEARCH) database (n= 4268)




Figure 1. Cumulative incidence curve for prostate cancer-specific mortality (PCSM) by obesity groups.

Vidal AC et al., Prostate Cancer and Prostatic Diseases (2017) 20, 72–78




Zhang X, Oncology Letters, 2015 Mar; 9(3): 1307–1312




OBESITY AND COLON CANCER SURVIVAL

Low muscle mass is hidden behind the bulk of body weight

IT'S NOT ALL ABOUT THE NUMBER ON THE SCALE...




MUSCLE MATTERS



MUSCLE, FAT, LIFESTYLE AND CANCER SURVIVORS

- Fatigue and reduced physical functioning commonly experienced long-term effects
- Survivors often become deconditioned and lose muscle mass during treatment leading to declines in physical functioning
- Muscle loss is not always apparent from monitoring weight even when weight is stable, survivors can be replacing muscle mass with fat mass (sarcopenic obesity) – weight gain exacerbates negative effects of muscle loss
- Weight loss not necessarily the answer- weight loss without exercise and adequate dietary
 protein can contribute to further muscle loss
- Cancer survivors with sarcopenic obesity those with high body fat and low muscle mass at highest risk for mortality
- Physical activity, high diet quality, and weight management may ameliorate many of the problems
- Substantial evidence supports the benefits of physical activity, diet, and weight management interventions cancer-related symptoms, improved quality of life, functional health outcomes

Biological Framework



ACS Guidelines on Nutrition and Physical Activity for Cancer Survivors

Get to and stay at a healthy weight.

• If you are overweight or obese, limit how much you eat of high-calorie foods and beverages and increase physical activity to promote weight loss.

Be active.

- Avoid inactivity and return to normal daily activities as soon as possible after diagnosis.
- Aim to exercise at least 150 minutes per week.
- Include strength training exercises at least 2 days per week.

Eat a variety of healthy foods from plant sources.

- Limit the amount of processed meat and red meat you eat.
- Eat $2^{1/2}$ cups or more of vegetables and fruits each day.
- Choose whole grains rather than refined grain products.

BEHAVIORS, COMORBIDITIES, QUALITY OF LIFE AND SURVIVORS FROM UNDERREPRESENTED MINORITY SURVIVORS

- Low adherence to nutrition and physical activity guidelines
- High rates of obesity-related comorbidities
- More likely to report fair-poor health status compared to minority controls and other survivors



Dennis-Parker et al., Integrative Cancer Therapies, 2014;13:114-120; Paxton R et al, Cancer, 2012;118:4024; Nayak P et al. *Am J Prev Med.* 2015;48(6) 729-736; Nichols HB et al., *Cancer Epidemiol Biomarkers Prev.* 2009;18(5):1403-1409; Weaver KE, J Cancer Surviv, 2013;7:253-261; Tammamagi et al Ansa B et al., International Journal of Environmental Research and Public Health; Stolley MR, Health Education and Behavior





FIGURE 1—Effect of biological, behavioral, clinical, and nonclinical factors on disease pathways in cardiovascular disease (CVD) and cancer: Transdisciplinary Cardiovascular and Cancer Health Disparities Training. Golden et al.,


DEVELOPING LIFESTYLE PROGRAMS WITH SURVIVORS FROM UNDERREPRESENTED GROUPS



Framework for Research Agenda:

Biopsychosocial framework to address cancer disparities and obesity that integrates biological, behavioral and community based

research.



STRATEGIES FOR ENHANCING CULTURAL APPROPRIATENESS

- **Peripheral**: give programs or materials the appearance of cultural appropriateness (i.e., logo, recruitment materials, exercise session music)
- Evidential: enhance the perceived relevance of a health issue for a given group by presenting evidence of its impact on that group (i.e., prostate cancer disparities, impact of obesity, comorbidities in the AA community)
- Linguistic: make health education programs and materials more accessible by providing them in the dominant or native language of target group
- **Constituent-Involving:** draw directly on the experiences of the target group (i.e., hire staff who represent target group; inform intervention using qualitative data from target group; have advisory group to provide feedback on study materials and procedures)
- **Sociocultural:** discuss health-related issues in the context of broader social and/or cultural values (i.e., honoring woman's central role in families, cancer fatalism and stigma, machismo or the central role of masculinity, body image ideals, and the traditional roles of food)




MOVING FORWARD N= 246 African American Breast Cancer Surviv



- 6-month weight loss intervention
 - Guided: 2x weekly meetings with supervised exercise, 2x weekly text messaging


Program binder, Newsletter

- Self-Guided: Program Binder, Monthly calls, Newsletter
- Primary outcome: weight loss
- Secondary outcomes: behavior, biomarkers, quality of life
- 6-month retention 86%: 12-month intervention 84%





ANTHROPOMETRICS





Caloric Intake: (p<0.03)

- Guided:
- Self-Guided:

-563.9 (72.6) -226.2 (75.8)

% Calories from Fat: (ns)

• Guided: Self-Guided:

22.19 (0.74) 20.67 (0.77)

Fiber (g/1000kcal) (p<0.001)

- Self-Guided:

• Guided: 3.24 (0.33) 0.91 (0.35)

Added Sugars (tsps./day) p= 0.03) • Guided: -6.98 (1.02)

Self-Guided:

-3.85 (1.06)


PHYSICAL ACTIVITY

Moderate Activity: ns Guided: +98.4 (0.42) mins/day Self-Guided: mins/day


+60.6 (0.44)

Vigorous Activity: (p=0.03) Guided: +17.4 (0.08) mins/day Self-Guided: + 2.4 (0.08) mins/day

BIOMARKER RESULTS








Biological Pathways' Results


Improved diet and physical activity patterns



LIFESTYLE AND SURVIVORSHIP-RELATED EFFORTS IN MILWAUKEE



PROSTATE CANCER





- Health Behaviors contribute to body composition, but also contribute to prostate cancer related outcomes (HPFS and CaPSure)
 - Diet
 - Animal fat increases risk for disease progression, PC specific and overall mortality
 - Adherence to Mediterranean diet associated with decreased all cause mortality
 - Fatty fish protective against disease progression
 - High cruciferous vegetable consumption associated with 58% decreased risk of PC progression
 - Physical Activity Active men have better outcomes
 - 57% lower risk of disease progression among men walking 3+ mph
 - 61% reduced risk for overall and PC specific mortality for men who exercised ≥ 3 hours/ week of vigorous activity compared to those who exercised <1 hour/week

Kenfield SA et al *J Clin Oncol.* 2011;29(6):726-732; Di Sebastiano KM et al., *Nutrients.* 2014;6(12):6095-6109; Chan JM et al., *Cancer Causes Control.* 2006;17(2):199-208; Richman EL et al., *JAMA Intern Med.* 2013;173(14):1318-1326; Kenfield SA et al., *Eur Urol.* 2014;65(5):887-894; Richman EL et al., *Int J Cancer.* 2012;131(1):201-210.



AFRICAN AMERICAN PROSTATE CANCER SURVIVORS

EXPLORATORY STUDY

Diet and Physical Activity Patterns

Variable	Mean (SD)		
Dietary Intake ¹			
Saturated fat, grams	21.2 (8.9)		
Added Sugar, grams	60.7 (53.4)		
Fiber, grams	12.1 (5.2)		
Fruits, cup equivalents	1.7 (1.3)		
Vegetables, cup equivalents	1.6 (0.8)		
Physical Activity ²	N (%)		
Insufficiently Active	18 (81.8)		
Sufficiently Active	4 (18.2)		
Resistance ex 2x/wk	2 (0.09)		



EXPLORATORY STUDY:

SURVEY: DIET, PHYSICAL ACTIVITY, QUALITY OF LIFE

FOCUS GROUP: UNMET NEEDS INTEREST IN LIFESTYLE PROGRAM

Diet and Physical Activity Patterns

Variable	Mean (SD)		
Dietary Intake ¹			
Saturated fat, grams	21.2 (8.9)		
Added Sugar, grams	60.7 (53.4)		
Fiber, grams	12.1 (5.2)		
Fruits, cup equivalents	1.7 (1.3)		
Vegetables, cup equivalents	1.6 (0.8)		
Physical Activity ²	N (%)		
Insufficiently Active	18 (81.8)		
Sufficiently Active	4 (18.2)		
Resistance ex 2x/wk	2 (0.09)		

QUALITY OF LIFE

¹ US average = 50, SD=10;

² Includes the 10 men who reported sexual activity (either with or without a partner);

Note: 3 point difference considered clinically meaningful




PROMIS Domains ¹						
Domain	AAPCS	SEER PCS	Gen'l Pop			
	Mean	Mean	Mean			
	(SD)	(SD)	(SD)			
Physical Function	45.3 (9.5)	50.2 (0.3)	50 (10)			
Depression	49.1 (9.0)	45.4 (0.3)	50 (10)			
Anxiety	50.1 (7.1)	45.9 (0.3)	50 (10)			
Fatigue	50.4 (10.8)	47.3 (0.3)	50 (10)			
Sleep Disturbance	52.0 (7.4)	48.2 (0.3)	50 (10)			
Ability to participate in Social Roles and Activities	51.0 (8.5)	55.1 (0.3)	50 (10)			
Pain Interference	54.7 (9.7)	49.1 (0.3)	50 (10)			
Social Isolation	43.9 (7.3)	NA	50 (10)			
Sexual Functioning ²						
Interest in Sexual Activity	41.6 (8.1)	NA	50 (10)			
Erectile Functioning	43.6 (4.5)	NA	50 (10)			

DISCUSSION SESSION RESULTS


Unhealthy Eating Patterns

- Need for increased diet related
- knowledge and skills
- Limited access to healthy eating resources
- Financial challenges



 Challenges
 Limited social support concerns
 Information

INTERVENTION RECOMMENDATIONS







RANDOMIZED EFFICACY TRIAL WITH 200 AAPCS (2019-2023)

Collaborators: Drs. Banerjee, Bylow, Flynn, Kilari, Gann (UIC), Papanek (Marquette), Sheean (Loyola Chicago),

- Test the effects of a 16-week guided vs self-guided nutrition and physical activity intervention on:
 - Behavior diet, physical activity
 - Body composition and strength percent body fat, percent lean mass, strength
 - Biomarkers adiponectin, leptin, C-peptide, IGF-1, IGFBP-3, C-Reactive Protein, estradiol, testosterone and sex hormone binding globulin
 - Exploratory Mitochondrial function and miRNA
- Partnership with Milwaukee Public Rec program currently held at North Division High School

Biological Framework





DATA COLLECTION


Interview: diet, physical activity, quality of life, selfefficacy social support, perceived access to healthy eating and exercise esources, urban life stress

Physical Assessment: blood draw, DEXA scan, height/weight, waist circumference, strength, blood pressure, sit to stand, hand grip

ELIGIBILITY CRITERIA

- Diagnosed with non-metastatic prostate cancer
- Active surveillance OR have completed all treatments at least 6-months prior to study participation
- BMI ≥ 25 kg/m²
- Physically able to participate in moderate physical activity as documented by provider approval







ACS GUIDELINES

ou eat

Be active

- Avoid inactivity
- Aim to exercise at least 150 minutes per week
- Include strength training exercises at least two days per week

INTERVENTION COMPONENTS

- Curriculum Binder
- Twice weekly classes
 - 2 hours 1 hour with group learning and support; 1 hour supervised exercise
 - 1 hour supervised exercise
- Twice weekly text messaging targeting self-efficacy, social support, environmental resources
- Pedometer, resistance band



WEEK 4, THE TAKEAWAY

What is plant based eating and How do I get started?

Simply put, plant based eating is making sure your plate is mostly filled with food from plants. Vegetables, fruits, whole grains, nuts, legumes (beans), and healthy oils (like olive).



How do I eat plant based?

Ideally, your plate at breakfast, lunch and dinner is mostly plant-based foods. Make whatever changes you can so that your meals begin to look like the picture on the next page. A healthy plant based meal should consist of portions of vegetables, fruits, whole grains, healthy protein and healthy oils.

WEEKLY TOPICS

- Week 1 Lifestyle and prostate cancer.
- Week 2 Stress and your mind, body, and behavior.
- Week 3 American Cancer Society Nutrition and Physical Activity guidelines.
- Week 4 Cooking Demo
- Week 5 Why do body fat and muscle matter?
- Week 6 Eating Plant-Based Affordably
- Week 7 How We Make Behavior Changes...
- Week 8 Cooking Demo
- Week 9 Conversations with a cancer doc
- Week 10 Sexual Health: Can lifestyle make a difference?
- Week 11 Lifestyle activity, exercise and strength training

Week 12 Cooking Demo

- Week 13 Addressing Barriers
- Week 14 Maintaining Changes
- Week 15 Knowing your motivators
- Week 16 Graduation and final cooking demonstration





Are you an African-American prostate cancer survivor?

Would you like to get stronger, feel better and have more energy?



To participate you have to...

- Self-identify as Black or African-American;
- Be 18 years or older;
- Have completed treatment for prostate cancer at least six months prior;
- Have access to a mobile phone.
- If you are eligible and agree to participate you will receive:
- Twice-weekly exercise sessions and nutritional education
- Supportive text messages
- Monthly group cooking classes

For more information and to sign up please contact us at (414) 955-4095 or email mmf@mcw.edu



- Aim 1. To adapt the Moving Forward weight loss intervention for overweight/obese Hispanic BCS.
 - Aim 2. To conduct a randomized pilot with 40 to establish the feasibility and explore the effects of Avanzando Juntas on anthropometric, behavioral, psychosocial and biological outcomes.

Figure 1: Adaptation Process Focus group I (4 groups, 6-8 women): Identify needs and culturally relevant elements to be integrated into adapted MF

Program Adaptation I (in collaboration w/Advisory Committee): Adapt MF manual to include elements identified in focus group

Ψ

Focus group II (same groups of women as in Focus Group 1): Review adapted manual and check for cultural relevance

Program Adaptation II (in collaboration w/Advisory Committee): Refine manual to integrate focus group feedback

Collaborators: Drs. Banerjee, Kamaraju, Young, Sheean (Loyola) Partnership with United Community Center

National Cancer Institute R21CA155688



- Explore feasibility, safety and efficacy of 12-week coach-supported lifestyle intervention
- 40 women with stable metastatic breast cancer randomized to immediate intervention and wait list control
- Primary outcome: Quality of Life
- Secondary outcomes: Body composition, strength, biomarkers of inflammation, mitochondrial function
- Preliminary results:
 - Feasible and safe
 - Significant improvement in quality of life, strength, fatigue, mitochondrial function

Collaborators: Dr. Chitambar, Dr. Banerjee, Dr. Sheean (Loyola Chicago)

Funded by National Cancer Institute R21CA218888

SUMMARY

- Obesity as defined by adiposity and muscle impacts cancer survivorship through quality of life and health outcomes
- Lifestyle determines body composition AND also impacts quality of life and health outcomes
- Supporting patients in lifestyle change is critical to their wellbeing
- Understanding why lifestyle matters scientifically can inform your work with patients
- Joining with researchers to study lifestyle and cancer will help move the science forward

THANK YOU TO COLLEAGUES

Anjishnu Banerjee, PhD Katie Bylow, MD Katheryn Flynn Deepak Kilari, MD Ken Jacobsohn, MD William See, MD Alexis Visotcky, MS Paula Papanek, PhD (Marquette) Patricia Sheean, PhD (Loyola)



Sophia Abogaye Jamal Jarett, MPH Kathleen Jensik, MSW Tina Johnson Ana Manriquez Prado Lauren Matthews, MPH Jermaine Murry Alexis Visotcky, MS

Leonard Wilson AND MPS REC

THANK YOU



